Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Long-term safety and effectiveness of Dengvaxia in the Philippines

Award Number: R01AI186073
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 08/01/2024
PERIOD OF PERFORMANCE END DATE: 06/30/2029

Group Awards By:

View Award Description

Long-term safety and effectiveness of Dengvaxia in the Philippines - Modified Project Summary/Abstract Section The four serotypes of dengue virus (DENV1–4) are the leading cause of mosquito-borne viral diseases in humans. Dengvaxia, the first licensed dengue vaccine, was recommended for individuals aged 9–45 years in 2016. In the Philippines, a school-based vaccination program was launched in April 2016 with >830,000 children receiving Dengvaxia without prior serological testing. Subsequently, DENV-seronegative children who received Dengvaxia developed severe disease after breakthrough DENV infection (BTDI). This resulted in the revised recommendation in 2018 that Dengvaxia be administered only to DENV-seropositive individuals. Thus, thousands of Filipino children are at higher risk of severe dengue disease. Studies have shown the efficacy of Dengvaxia waned over time especially among baseline DENV-seronegative recipients, underscoring a critical need for elucidation of antibody and T-cell responses induced by Dengvaxia. Our understanding of Dengvaxia was primarily based on efficacy trials with 3-dose regimen. A knowledge gap exists regarding the risk of severe disease and effectiveness in the real world, where most individuals received only 1 or 2 doses and presented with BTDI. Our recent study demonstrated the feasibility of our DENV1–4 nonstructural protein 1 (NS1) IgG ELISA to determine the baseline DENV serostatus of Dengvaxia recipients during both BTDI and other febrile illness (OFI) in the Philippines. Our long-term goal is to facilitate the development of next-generation dengue vaccines and to reduce the global disease burden of dengue. The objective is to understand the long-term effects and immune responses induced by Dengvaxia, a chimeric yellow fever tetravalent dengue vaccine in the Filipino population. The central hypothesis is that Dengvaxia induces antibody and T-cell responses inferior to natural infection, leading to limited type-specific neutralizing antibodies, weak T-cell responses and waning vaccine efficacy especially for baseline DENV-naïve recipients. The first aim is to determine the baseline DENV serostatus of Dengvaxia recipients in the Philippines and assess the long-term safety and effectiveness of Dengvaxia. The second aim is to characterize antibody and T-cell responses induced by Dengvaxia prior to and after BTDI. The proposed research is innovative as it combines RT-PCR and IgM ELISA used in routine dengue fever surveillance and our recently validated DENV1−4 NS1 IgG ELISA to determine baseline DENV serostatus under field conditions and provides new insights into the safety and effectiveness of Dengvaxia after mass vaccination through a manufacturer-independent study as opposed to that derived from vaccine efficacy trials. Given that previous immunogenicity studies of Dengvaxia primarily focused on neutralizing antibody titers, our in-depth study of antibody responses both qualitatively and quantitatively and T-cell responses to structural and nonstructural proteins is highly significant. This information is translational and will facilitate the development of next-generation live-attenuated tetravalent dengue vaccine or other chimeric vaccines.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $503,085 )
2026	2026	UNIVERSITY OF HAWAII	2425 CAMPUS RD SINCLAIR RM 1	HONOLULU	HI	96822	HONOLULU	USA	Allergy and Infectious Diseases Research	000	3	7/17/2026	NON-COMPETING CONTINUATION	$503,085
														Subtotal = $503,085

Issue Date FY: 2025 ( Subtotal = $402,025 )
2025	2025	UNIVERSITY OF HAWAII	2425 CAMPUS RD SINCLAIR RM 1	HONOLULU	HI	96822	HONOLULU	USA	Allergy and Infectious Diseases Research	000	2	9/17/2025	NON-COMPETING CONTINUATION	$402,025
														Subtotal = $402,025

Issue Date FY: 2024 ( Subtotal = $615,068 )
2024	2024	UNIVERSITY OF HAWAII	2425 CAMPUS RD SINCLAIR RM 1	HONOLULU	HI	96822	HONOLULU	USA	Allergy and Infectious Diseases Research	001	1	9/4/2024	NEW	$60,095
2024	2024	UNIVERSITY OF HAWAII	2425 CAMPUS RD SINCLAIR RM 1	HONOLULU	HI	96822	HONOLULU	USA	Allergy and Infectious Diseases Research	000	1	7/30/2024	NEW	$554,973
														Subtotal = $615,068

Grand Total All Awards = $1,520,178

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Long-term safety and effectiveness of Dengvaxia in the Philippines

Award Number: R01AI186073

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 08/01/2024

PERIOD OF PERFORMANCE END DATE: 06/30/2029

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer